CTNM
Contineum·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Consensus Rating "Buy"
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CTNM
Contineum Therapeutics, Inc.
A clinical-stage biotechnology company focused on the fields of neurology, inflammation, and immunology.
10578 Science Center Drive, Suite 200 San Diego, California 92121
--
Contineum Therapeutics, Inc., was incorporated in Delaware in 2009 as Versense Pharmaceuticals, Inc. (Versense). In November 2023, the company changed its name to Contineum Therapeutics, Inc. The company is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral small molecule therapies for NI & I indications with high unmet need. They target biological pathways associated with specific clinical injuries that, they believe, once regulated, will significantly alter the course of the disease.
Company Financials
EPS
CTNM has released its 2025 Q3 earnings. EPS was reported at -0.45, versus the expected -0.46, beating expectations. The chart below visualizes how CTNM has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
